Literature DB >> 7332728

Pharmacokinetics of sustained release theophylline in low and high multidose regimens.

G H Koëter, J H Jonkman, K de Vries, R Schoenmaker, J E Greving, R A de Zeeuw.   

Abstract

1 The in vitro characteristics (dissolution rate) of a sustained release theophylline preparation (Theo-Dur were first measured in acid medium (pH = 1) for 2 h and after that in a phosphate buffer (pH = 6.8) for 6 h. 2 The tablets released more than 95% of the active ingredient within 5 h at a rate of approximately 11% of the dose per hour at pH = 1 and about 18% at pH = 6.8. 3 Dose dependency of the pharmacokinetics of theophylline was tested in seven healthy volunteers by giving them either 300 mg Theo-Dur or 900 mg Theo-Dur in two doses a day for 5 days in a cross over design. After the last tablet on day 6 the fall-off curve was followed in order to calculate the pharmacokinetic parameters. 4 Theophylline (300 mg) resulted on day 6 in a mean serum concentration of 4.4 +/- 0.8 microgram ml-1. The dose of 900 mg resulted in a proportional increase in the serum concentration. The result was 13.3 +/- 2.2 micrograms ml-1. 5 The T1/2 (300 mg) was 9.3 +/- 1.4 h and the T1/2 (900 mg) was 8.5 +/- 2.0 h. These values do not significantly differ (0.10 less than P less than 0.20). 6 It was concluded that theophylline exhibits the rules of linear pharmacokinetics when serum concentrations are in the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332728      PMCID: PMC1401956          DOI: 10.1111/j.1365-2125.1981.tb01283.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Relationship of urinary metabolites of theophylline to serum theophylline levels.

Authors:  J W Jenne; H T Nagasawa; R D Thompson
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

2.  Dose-dependent kinetics of theophylline disposition in asthmatic children.

Authors:  M Weinberger; E Ginchansky
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

Review 3.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

4.  The relation of product formulation to absorption of oral theophylline.

Authors:  M Weinberger; L Hendeles; L Bighley
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

5.  Acute theophylline intoxication. Biphasic first order elimination kinetics in a child.

Authors:  G J Kadlec; C H Jarboe; S J Pollard; J L Sublett
Journal:  Ann Allergy       Date:  1978-12

6.  Temporal variations in trough serum theophylline concentrations at steady state.

Authors:  L J Lesko; D Brousseau; A T Canada; G Eastwood
Journal:  J Pharm Sci       Date:  1980-03       Impact factor: 3.534

7.  Metabolism of theophylline (1,3-dimethylxanthine) in man.

Authors:  B B BRODIE; J AXELROD; J REICHENTHAL
Journal:  J Biol Chem       Date:  1952-01       Impact factor: 5.157

8.  Effects of allopurinol on theophylline metabolism and clearance.

Authors:  J J Grygiel; L M Wing; J Farkas; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

9.  Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia.

Authors:  J R Powell; S Vozeh; P Hopewell; J Costello; L B Sheiner; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1978-08

10.  Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation.

Authors:  J H Jonkman; G H Koëter; R Schoenmaker; K de Vries; J E Greving; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  12 in total

1.  Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways.

Authors:  S Dadashzadeh; H Tajerzaden
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

2.  Protective effect of oral oxyphenonium bromide, terbutaline and theophylline against the bronchial obstructive effects of inhaled histamine, acetylcholine and propranolol.

Authors:  G H Koëter; H Meurs; J H Jonkman; J Greving; J Leferink; H J Sluiter; R A de Zeeuw; K de Vries
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Bioavailability and pharmacokinetics of theophylline following plain uncoated and sustained-release dosage forms in relation to smoking habit. II. Multiple dose study.

Authors:  T Ishizaki; Y Horai; T Sasaki; K Chiba; A Ohnishi; T Suganuma; G Tsujimoto; H Echizen; T Okaniwa
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Lack of dose dependent kinetics of theophylline.

Authors:  P J Brown; L J Dusci; G M Shenfield
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.

Authors:  J G Wagner
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 6.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  Theophylline pharmacokinetics following single and repeated administration of slow-release capsules.

Authors:  J Torrent; I Izquierdo; M J Barbanoj; R Obach; M Nomen; F Jane
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

8.  Prediction of optimum oral theophylline dose in patients with obstructive airways disease.

Authors:  D R Taylor; C D Kinney; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

9.  Pharmacokinetics of theophylline: a dose-range study.

Authors:  V Rovei; F Chanoine; M Strolin Benedetti
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

10.  Components of variability in serum theophylline concentrations during maintenance therapy with a sustained release formulation.

Authors:  H Halkin; A Mazar; S Almog; Y Schnaps
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.